| Biomarker ID | 839 |
| PMID | 22240788 |
| Year | 2012 |
| Biomarker | mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | metastatic prostate cancer Vs localised prostate cancer |
| Type of Biomarker | Diagnostic |
| Cohort | prostate cancer cases (n=78) were selected along with (n=28) normal cases. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | mir-582-3p, mir-20a*, mir-375, mir-200b, mir-379, mir-572, mir-513a-5p, mir-577, mir-23a*, mir-1236, mir-609, mir-17*, mir-619, mir-624*, mir-198, mir-130b |